SKY92 Identifies High-Risk Newly Diagnosed Multiple Myeloma With Inferior Progression-Free Survival and Implicates
Roisin M McAvera1,2, Izabela Cymer1, John Quinn3
1Multiple Myeloma Research Group, Royal College of Surgeons in Ireland, Dublin, Ireland.
Objectives:
To determine the prevalence and prognostic significance of the SKY92 gene-expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high-risk disease in transplant-eligible newly diagnosed multiple myeloma (TE-NDMM) patients in the Republic of Ireland.
Methods:
Baseline genomic risk was assessed using the MMprofiler microarray in 114 TE-NDMM patients. MRD was evaluated 100 days after autologous stem cell transplantation using next-generation sequencing at the International Myeloma Working Group-recommended sensitivity of 10-5. Differential gene expression and copy number analyses were performed and compared with digital MLPA and retrospective fluorescence in situ hybridisation (FISH).
Results:
SKY92 classified 25.4% (29/114) of patients as high-risk and was associated with inferior progression-free survival and other adverse disease features. MRD assessment achieved 10-5 sensitivity, although MRD negativity was not associated with SKY92 risk status. High-risk disease demonstrated enrichment of pathways involved in chromosomal stability and DNA repair. NUF2 emerged as a key independent prognostic marker, showing strong association with high-risk biology and identifying a potential molecular driver of aggressive disease. Copy number abnormality detection showed high concordance between MMprofiler, digital MLPA, and retrospective FISH.
Conclusions:
This first characterisation of SKY92-defined high-risk multiple myeloma in Ireland supports integrated genomic profiling for clinical risk stratification and identifies NUF2 as a promising candidate driver, demonstrating that deep profiling of high-risk disease may help to discover new targets for this challenging entity.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...